PATENT '

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

Wolfgang M. FRANZ et al. Conf.:

2640

Appl. No.:

09/068,751

Group:

1635

Filed:

November 2, 1998

Examiner: M. Schmidt

For:

GENE-THERAPEUTIC NUCLEIC ACID

CONSTRUCT, PRODUCTION OF SAME AND USE

OF SAME IN THE TREATMENT OF HEART

DISEASE

LARGE ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents Washington, DC 20231

December 4, 2001

Sir:

Transmitted herewith is an amendment in the above-identified application.

The	enclose	d document	is	being	transm	itted	via	the	Certificate
of	Mailing	provisions	of	37 C	F.R. §	1.8.			

The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	26	-	58	=	0	\$18	\$0.00
INDEPENDENT	4	-	1		0	\$84	\$0.00
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM \$280 \$0.0							\$0.00
						TOTAL	\$0.00

Appl. No. 09/068,751

(Rev. 09/27/01)

		month(s) extension of time pursuant to 1.136(a). \$0.00 for the extension of
\boxtimes	No fee is required.	
	Check(s) in the amount	of \$0.00 is(are) enclosed.
	Please charge Deposit A \$0.00. This form is sub	Account No. 02-2448 in the amount of mitted in triplicate.
over requ	urrent, and future repli payment to Deposit Accour	ssioner is hereby authorized in this, les, to charge payment or credit any at No. 02-2448 for any additional fees 1.16 or under 37 C.F.R. § 1.17; ime fees.
		Respectfully submitted,
		BIRCH, STEWART, KOLASCH & BIRCH, LLP
		By mh Null #36,623 Mark U. Nuell, #36,623
DRN/0	crt -0110P	P.O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000

ATTACHMENT

Docket No. 0690-

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Wolfgang M. FRANZ et al. Conf:

2640

APPLN. NO.:

09/068,751

GROUP:

1635

FILED:

November 2, 1998

EXAMINER: M. Schmidt

FOR:

GENE-THERAPEUTIC NUCLEIC ACID CONSTRUCT, PRODUCTION OF SAME AND USE OF SAME IN THE

TREATMENT OF HEART DISEASE

AMENDMENT

Assistant Commissioner of Patents Washington, DC 20231

December 4, 2001

Sir:

Further to the Request for Continued Examination filed September 28, 2001 and the interview with the Examiner held November 16, 2001, the following amendments and remarks are respectfully submitted.

In the Specification:

Please replace the second paragraph beginning on page 15, line 7/with the following rewritten paragraph:

-- Figs. 10A-C show the nucleic acid sequence of a 2216 base pair-long promoter of the MLC-2v gene of rats (SEQ.ID. NO:1), lying upstream of the transcription starting point (+1). nucleic acids of positions 1-156 encode for the packaging